Search within Therapeutic Immunology Group Web Site:
List of monoclonal antibodies produced by TIG/Waldmann Group
Anti-mouse * Anti-canine * Anti-human
* Antibodies marked with asterisk are hybridomas with rat myeloma Y3/Ag1.2.3 and are available for academic purposes (via a request form here). Many of these antibodies and their hybridomas are also available for commercial licensing from Cambridge Enterprise. Where indicated, the hybridoma cell lines are also available from the European Collection of Cell Cultures (ECACC).
Anti-mouse antibodies:
| Antibody | Specificity | Isotype (rat) | Comments | Antibody/conjugates available commercially: | Main applications | ECACC catalogue |
| YTS 109.8.1.1 | Thy-1 | IgM | In vitro depletion (+c') | ..... | In vitro T cell depletion | .... |
| YTS 111.4.2* | Thy-1 | IgG2a | ..... | ..... | ..... | .... |
| YTS 148.3.2.1* | Thy-1 | IgM | In vitro depletion (+c') | ..... | ..... | .... |
| YTS 154.7.7.10* | Thy-1 | IgG2b | In vivo depleting | Was Harlan, now: Serotec | T+NK cell depletion in vivo | 87072285 |
| YBM 29.2.1* | Thy-1 | IgG2c | In vitro depletion (+c') | ..... | In vitro T cell depletion/FACS | 11060806 |
| YCTLD 45.1* | Thy-1 | IgG2c | ..... | ..... | ..... | .... |
| YCTLD 160.101* | Thy-1 | IgG2c | Mitogenic for T cells | ..... | ..... | .... |
| NSM 46.7 | CD2 | IgG2a | Domain 2 | ..... | FACS staining | .... |
| YTS 121.5.2* | CD5 (Lyt-1) | IgG2b | In vivo depleting | Was Harlan, now: Serotec | T cell depletion in vivo/FACS | 87072283 |
| YTS 166.2.16* | CD5 (Lyt-1) | IgG2c | ..... | ..... | ..... | .... |
| YTS 191.1.2* | CD4 Epitope A | IgG2b | In vivo depleting | Serotec/Cedarlane | CD4 subset depletion in vivo/FACS | 87072282 |
| YTS 177.9.6.1* | CD4 Epitope A | IgG2a | In vivo blocking | Serotec | Peripheral tolerance induction/FACS stain | 11060819 |
| YTA 3.1.2* | CD4 Epitope B | IgG2b | In vivo depleting | Was Harlan, now: Serotec | CD4 subset depletion in vivo/FACS | 89040603 |
| YTS 169.4.2.1* | CD8 (Lyt-2) | IgG2b | In vivo depleting | Serotec/Cedarlane | CD8 subset depletion in vivo/FACS | 87072284 |
| YTS 105.18.10* | CD8 (Lyt-2) | IgG2a | In vivo blocking | Serotec | CD8 T cell blockade in vivo/FACS stain | 11060802 |
| YTS 156.7.7* | CD8 (Lyt-3) | IgG2b | In vivo depleting | Was Harlan, now: Serotec | CD8 subset depletion in vivo/FACS | 89040604 |
| YBM 15.1.6* | CD11b | IgG2b | anti-CR3 | ..... | FACS staining | 89040602 |
| YBM 6.1.10* | CD11b | IgG2a | anti-CR3 | ..... | FACS staining | 89040601 |
| YTS 213.1.1* | CD18 | IgG2a(Does not block function) | ..... | Serotec | FACS staining | 11060803 |
| YMSM 636.4 | CD30 | IgG2b | ..... | Serotec | Activation antigen (IL-4 dependent?)/FACS | .... |
| YBM 42.2.2* | CD45 (pan) | IgG2a | ..... | ..... | FACS staining/Immunoppt./western blot etc. | .... |
| YW 62.3.20* | CD45 | IgG2b | Synergistic pair | Serotec/Cedarlane | FACS staining | 11072202 |
| YTS 165.1* | CD45 | IgG2b | Synergistic pair | ..... | Haemopoietic cell depletion (with YW 62.3) | .... |
| YW 13.1.1* | CD45R? | IgG2b | ..... | ..... | Sorting haemopoietic cell precursors | .... |
| YBM 10.14.2* | HSA? | IgG2c | ..... | ..... | ..... | .... |
| YBM 5.10.4* | HSA | IgM | Heat Stable Antigen | ..... | Thymocyte subsets/depletion of B cells in vitro | 11060805 |
| YTA 74.4.4* | CD71 | IgG2a | Transferrin Receptor | Serotec | Activation antigen/FACS staining | 11060804 |
| YTA 94.8.10* | MHC-II | IgG2b(IAk+IEk+?) | ..... | ..... | ..... | .... |
| YLAG 77.5 | LAG-3 | IgG2b | ..... | Serotec | Activation antigen (IFN-g dependent)/FACS | .... |
| YGITR 765.4.2 | GITR (TNFSFR18) | IgG2b | ..... | To be Advised | T cell costimulation/FACS | .... |
| YGITR 860.14.7 | GITR (TNFSFR18) | IgG2b | ..... | To be Advised | T cell costimulation/FACS | .... | YGL 386.2.2 | GITRLigand | IgG1 | ..... | To be Advised | Antigen presenting cell function/FACS | .... |
Anti-canine antibodies:
| Antibody | Specificity | Isotype (rat) | Comments | Antibody/conjugates available commercially: | Main applications | ECACC catalogue |
| YKIX 302.9.3* | CD4 | IgG2a | In vivo blocking | Serotec | Immunosuppression/FACS staining | .... |
| YKIX 322.3.2* | CD5 | IgG2a | ..... | Serotec | FACS staining (T cells) | .... |
| YCATE 55.9.1* | CD8 | IgG1 | CD8 alpha | Serotec | FACS staining/blocking | .... |
| YKIX 490.6.4* | CD11/18 | IgG2c | In vitro blockade | Serotec | Functional studies | .... |
| YKIX 337.8.7* | CD44 | IgG2a | ..... | Serotec | FACS staining | .... |
| YKIX 716.13.2* | CD45(RB?) | IgG2b | In vitro killing (synergy) | Serotec | FACS staining/haemopoietic cell depletion | .... |
| YKIX 753.22.2* | CD45R(A?) | IgG2b | In vitro killing (synergy) | Serotec | FACS staining/haemopoietic cell depletion | .... |
| YKIX 739.46* | CLAW-H | IgG2a | possible CD59? | Serotec | Complement protection studies? | .... |
| YKIX 337.217* | Thy-1 | IgG2b | CDw90 | Serotec | FACS staining (T cells) | .... |
| YKIX 334.2.4* | MHC-II | IgG2a | Blocks MLR | Serotec | FACS staining/blocking | .... |
Anti-human antibodies
*** These anti-human hybridoma cell lines are subject to various license restrictions. ***
| Antibody | Specificity | Isotype (rat) | Comments | Antibody/conjugates available commercially: | Main applications | ECACC catalogue |
| YNB 46.1.8 | CD4 | IgG1 | Blocks function | Serotec | FACS staining/blocking | .... |
| YTH 30.15 | CD7 | IgG2b | ..... | Serotec | FACS staining | 11060807 |
| YTC 182.20 | CD8 | IgG2b | Synergistic pair | Serotec | FACS staining/in vitro depletion | .... |
| YTC 141.1HL | CD8 | IgG2b | Synergistic pair | Serotec | FACS staining/in vitro depletion | .... |
| YTH 81.5 | CD11a | IgG2a | Blocks function | Serotec | FACS staining/blocking | 11072203 |
| YFC 120.5 | CD16 | IgG2b | Blocks function | Serotec | FACS staining/blocking | 11060808 |
| YFC 118.12 | CD18 | IgG2b | Blocks function | Serotec | FACS staining/blocking | 11072204 |
| YTH 906.9HL | CD25 | IgG2b | Blocks function | Serotec | FACS staining/blocking | 11060809 |
| YTH 913.12 | CD28 | IgG2b | Blocks function | Serotec | FACS staining/blocking | 11060810 |
| YTH 24.5 | CD45 | IgG2b | ..... | Serotec | FACS staining | .... |
| YTH 80.103 | CD45R(C?) | IgG2b | ..... | Serotec | FACS staining | 11060811 |
| YTH 66.9 | CD52 | IgM | CAMPATH-1M | Serotec | Lymphocyte depletion/FACS staining | .... |
| YTH 34.5 | CD52 | IgG2b | CAMPATH-1G | Serotec | Lymphocyte depletion/FACS staining | .... |
| YTH 53.1 | CD59 | IgG2b | Mac inhibitor | Serotec | FACS staining/blocking | 11060813 |
| YTH 71.3 | CD66acd | IgG2a | ..... | Serotec | FACS staining | 11072205 |
| YTH 8.18 | nd | IgG2b | Neutros/macs cytoplasm | Serotec | Immunohistology | .... |
YTH 655*  | Human CD2 | IgG2b | Deplete foxp3.hCD2+ mouse Treg | See request form | FACS/in vivo depletion | .... |
| YTH 862.2 | HLA-class I | IgG2b | Cytotoxic/monomorphic | Serotec | FACS staining/blocking | 11060817 |
| YTH 470.5 | beta2-micro | IgG2b | Cytotoxic | Serotec | FACS staining/blocking | .... |
| YTH 89.1 | Glycophorin A (CD235a) | IgG2b | .... | .... | FACS staining | 11060814 |
| YAML 501.4 | CD45:all isoforms | IgG2a | .... | .... | FACS staining/immunohistology | 11060812 |
| YAML 555.6 | HLA-DR | IgG2a | .... | .... | FACS staining/immunohistology | 11060816 |
| YTH 76.3 | HLA-B | IgG2a | .... | .... | FACS staining | 11060815 |
*** These anti-human hybridoma cell lines are subject to various license restrictions. ***
"Developing short-term treatments for long-term outcomes"
Related topics:
Making mAbs in large (gram) amounts
Last Updated 20th October 2011 by Steve Cobbold